Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other 3

Conditions

Pain 3Intestinal Diseases 3Constipation 3Urinary Bladder Neoplasms 2Ovarian Neoplasms 1Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

alvimopan 3Bevacizumab 3Leucovorin 2Irinotecan 2Fluorouracil 2napabucasin 1encorafenib 1Oxaliplatin 1Oviposition 1Levoleucovorin 1Drug Therapy 1Drainage 1Cetuximab 1Capecitabine 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Intestinal Diseases × alvimopan × Clear all
NCT00241722 2017-08-30

Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3 Completed
805 enrolled
Other

Constipation, Intestinal Diseases, Pain

NCT00256932 2015-09-02

Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3 Completed
518 enrolled
Other

Constipation, Intestinal Diseases, Pain

NCT00259922 2015-09-02

Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3 Completed
485 enrolled
Other

Constipation, Intestinal Diseases, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡